Department of Hematology, Paris Descartes University, Hôpital Necker, Paris, France.
Leuk Lymphoma. 2013 Jan;54(1):41-5. doi: 10.3109/10428194.2012.698274. Epub 2012 Jul 9.
Tumor-associated macrophages (TAMs) might be associated with worse outcome in classical Hodgkin lymphoma (cHL). Our aim was to determine whether TAMs correlated with refractoriness in cHL. In a cohort of 18 consecutive primary refractory or early relapsed cases and 41 randomly selected controls (responder patients), high TAM infiltration was significantly associated with refractoriness or early relapse (p = 0.004) and remained independently correlated with outcome in multivariate analysis (odds ratio 8.276, 95% confidence interval 1.214-56.408). This study provides evidence that the marker CD68 might accurately predict early outcome of de novo cHL and could be used in combination with c-kit and TiA1 staining.
肿瘤相关巨噬细胞（TAMs）可能与经典型霍奇金淋巴瘤（cHL）的不良预后相关。我们的目的是确定 TAMs 是否与 cHL 的耐药性相关。在连续的 18 例原发性难治性或早期复发病例和 41 例随机选择的对照组（应答者患者）中，高 TAM 浸润与难治性或早期复发显著相关（p=0.004），并且在多变量分析中仍然与预后独立相关（比值比 8.276，95%置信区间 1.214-56.408）。这项研究提供了证据表明，标志物 CD68 可能能够准确预测初治 cHL 的早期结果，并且可以与 c-kit 和 TiA1 染色联合使用。
